• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化所致腹水成年患者的管理

Management of adult patients with ascites caused by cirrhosis.

作者信息

Runyon B A

机构信息

Loma Linda Transplantation Institute, CA 92354, USA.

出版信息

Hepatology. 1998 Jan;27(1):264-72. doi: 10.1002/hep.510270139.

DOI:10.1002/hep.510270139
PMID:9425946
Abstract

Ascites is the most common of the major complications of cirrhosis. The development of ascites is an important landmark in the natural history of cirrhosis and has been proposed as an indication for liver transplantation. The initial evaluation of a patient with ascites should include a history, physical evaluation, and abdominal paracentesis with ascitic fluid analysis. Treatment should consist of abstinence from alcohol, sodium restricted diet, and diuretics. This regimen is effective in approximately 90% of patients. The treatment options for the diuretic-resistant patients include serial therapeutic paracenteses, liver transplantation, and peritoneovenous shunting.

摘要

腹水是肝硬化最常见的主要并发症。腹水的出现是肝硬化自然病程中的一个重要标志,并且已被提议作为肝移植的指征。对腹水患者的初步评估应包括病史、体格检查以及进行腹水穿刺并分析腹水。治疗应包括戒酒、限制钠摄入饮食以及使用利尿剂。该治疗方案对大约90%的患者有效。对利尿剂抵抗患者的治疗选择包括系列治疗性腹腔穿刺放液、肝移植以及腹腔静脉分流术。

相似文献

1
Management of adult patients with ascites caused by cirrhosis.肝硬化所致腹水成年患者的管理
Hepatology. 1998 Jan;27(1):264-72. doi: 10.1002/hep.510270139.
2
Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.肝硬化腹水的治疗。利尿剂、腹腔静脉分流术及大量腹腔穿刺放液术。
Gastroenterol Clin North Am. 1992 Mar;21(1):237-56.
3
[How I treat ... ascites].[我如何治疗……腹水]
Rev Med Liege. 2001 Dec;56(12):809-15.
4
Management of ascites. A review.腹水的管理。综述。
J Med. 1997;28(1-2):21-30.
5
[Management of ascitis in patients with cirrhosis].[肝硬化患者腹水的管理]
Tunis Med. 2007 Feb;85(2):91-5.
6
Ascites: diagnosis and management.腹水:诊断与管理
Med Clin North Am. 2009 Jul;93(4):801-17, vii. doi: 10.1016/j.mcna.2009.03.007.
7
[Treatment of ascites in liver cirrhosis].[肝硬化腹水的治疗]
Ugeskr Laeger. 1994 Sep 12;156(37):5256-65.
8
Treatment of patients with cirrhosis and ascites.肝硬化腹水患者的治疗。
Semin Liver Dis. 1997;17(3):249-60. doi: 10.1055/s-2007-1007202.
9
[Treatment of cirrhotic ascites].[肝硬化腹水的治疗]
Schweiz Med Wochenschr. 1979 Jun 23;109(25):950-3.
10
The management of ascites and hyponatremia in cirrhosis.肝硬化腹水和低钠血症的管理
Semin Liver Dis. 2008 Feb;28(1):43-58. doi: 10.1055/s-2008-1040320.

引用本文的文献

1
Update on the Complications and Management of Liver Cirrhosis.肝硬化并发症与管理的最新进展
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
2
Spontaneous Bacterial Peritonitis: A Rare Complication of Pulmonary Arterial Hypertension.自发性细菌性腹膜炎:肺动脉高压的一种罕见并发症。
Biomedicines. 2024 Jun 22;12(7):1389. doi: 10.3390/biomedicines12071389.
3
Risk Factors and Comorbidities Associated With Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection.慢性乙型肝炎病毒感染患者肝细胞癌的相关风险因素和合并症。
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259413. doi: 10.1177/21501319241259413.
4
A Validated Composite Score Demonstrates Potential Superiority to MELD-Based Systems in Predicting Short-Term Survival in Patients with Liver Cirrhosis and Spontaneous Bacterial Peritonitis-A Preliminary Study.一项经过验证的综合评分在预测肝硬化合并自发性细菌性腹膜炎患者短期生存方面显示出优于基于终末期肝病模型(MELD)系统的潜力——一项初步研究。
Diagnostics (Basel). 2023 Aug 2;13(15):2578. doi: 10.3390/diagnostics13152578.
5
Effect of Hospital Teaching Status on Mortality and Procedural Complications of Percutaneous Paracentesis in the United States: A Four-Year Analysis of the National Inpatient Sample.美国医院教学状况对经皮穿刺腹腔穿刺术死亡率和手术并发症的影响:对全国住院患者样本的四年分析
Cureus. 2022 Jun 24;14(6):e26282. doi: 10.7759/cureus.26282. eCollection 2022 Jun.
6
How much is too much? Pushing the limits of fluid removal via paracentesis.多少才算过量?通过腹腔穿刺术进行液体抽取的极限探讨。
SAGE Open Med Case Rep. 2022 Jul 4;10:2050313X221109689. doi: 10.1177/2050313X221109689. eCollection 2022.
7
Prevalence and Clinical Implications of Ascites in Gastric Cancer Patients after Curative Surgery.胃癌患者根治性手术后腹水的患病率及临床意义
J Clin Med. 2021 Aug 13;10(16):3557. doi: 10.3390/jcm10163557.
8
Trends and outcomes of percutaneous endoscopic gastrostomy in hospitalized patients with malignant and nonmalignant ascites: a nationwide population study.住院恶性和非恶性腹水患者经皮内镜下胃造口术的趋势和结果:一项全国性人群研究。
Ann Gastroenterol. 2020 Nov-Dec;33(6):656-660. doi: 10.20524/aog.2020.0531. Epub 2020 Sep 16.
9
Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.茵陈蒿汤与螺内酯的药代动力学和药效学同时相互作用的临床前研究。
BMC Complement Med Ther. 2020 Aug 15;20(1):253. doi: 10.1186/s12906-020-03042-y.
10
H-NMR spectroscopy metabonomics of reactive, ovarian carcinoma and hepatocellular carcinoma ascites.反应性、卵巢癌和肝细胞癌腹水的氢核磁共振波谱代谢组学
Pleura Peritoneum. 2020 May 12;5(2):20200113. doi: 10.1515/pp-2020-0113. eCollection 2020 Jun 1.